Wearable device data may help detect and track idiopathic pulmonary arterial hypertension, a rare lung disease, a study ...

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial Hypertension (“PAH”), announced today that ...

With pulmonary hypertension (PH), a pulmonary artery wedge pressure (PAWP)>15 mm Hg is used to diagnose left heart dysfunction, but some patients with adjudicated group 1 PH demonstrate PAWP>15 mm Hg.

Early signs of pulmonary hypertension are relatively mild and mimic common conditions such as asthma, poor fitness or anxiety. [Courtesy] Many people are familiar with hypertension, commonly described ...

Pulmonary arterial hypertension (PAH) is a type of high blood pressure in the arteries that go from your heart to your lungs. It happens when these arteries become narrow or blocked, making it harder ...

Merck received positive results from a Phase 2 trial evaluating a treatment for pulmonary hypertension. Merck on Tuesday said its drug, Winrevair, met the primary endpoint in a Phase 2 study in adults ...

Treatment options for managing your PH will depend on what type of pulmonary hypertension you have. Each type of pulmonary hypertension requires a tailored treatment plan that follows the latest ...

Today, in honor of Pulmonary Hypertension Awareness Month, the American Lung Association, with support from Merck, launched a new campaign to educate and support people with a rare and ...

PH develops when chronic pulmonary vascular stress (e.g., increased pulmonary blood flow or pulmonary pressure, hypoxia, pulmonary vascular obstruction, primary endothelial dysfunction) leads to ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved an update to the U.S.